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ABSTRACT 
 G-protein-coupled receptors (GPCRs) are important pharmaceutical targets. In 
recent years, it has been found that GPCRs can function as homo- and hetero- dimers. 
The serotonin receptors 5-HT2AR and 5-HT2CR have been shown to form a heterodimer. 
These two receptors regulate impulsivity and cue reactivity, two factors that can lead to 
drug addiction relapse. A synergistic effect of the 5-HT2AR antagonist M100907 and the 
5-HT2CR agonist WAY163909 in the suppression of impulsivity and cue reactivity has 
been reported. A bivalent ligand containing these two pharmacophores, linked by a 
polyethylene glycol chain and a triazole, has been developed. 
 In this thesis, attempts to functionalize the linker portion of the bivalent ligand for 
the addition of a fluorophore are reported.  The first approach was to functionalize the 
triazole portion of the linker via the iodoalkyne-azide cycloaddition reaction; however, it 
was determined that this method was unsuitable due to challenges with purity and yield. 
The second approach was to functionalize the polyethylene glycol portion of the linker by 
replacing an oxygen atom with a nitrogen atom, allowing for tertiary substitution at the 
nitrogen. A linker was synthesized containing a tertiary amine in which an ester side-
chain was included. This ester serves as a handle for incorporation of a fluorophore via 
amide coupling. A fluorophore-tagged bivalent ligand will open the door to cellular 
imaging of the 5-HT2AR/5-HT2CR GPCR heterodimer.  
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Chapter I: Introduction to GPCR Dimers 
1.1 Discovery and Physiological Relevance of GPCR Dimers 
1.1.1 G-protein-coupled Receptors 
G-protein-coupled receptors (GPCRs) are proteins which span the cell membrane 
and transmit signals from the outside of the cell to the inside of the cell via activation of a 
G-protein, that is, a protein which binds guanosine triphosphate (GTP). The G-protein in 
turn activates a cascade of intracellular signaling. The roles of different GPCRs vary 
greatly; agonists for GPCRs include neurotransmitters, hormones, and even light. While 
there is a great diversity of structure and function within the GPCR superfamily, nearly 
all GPCRs are characterized by seven transmembrane α-helices, an extracellular N-
terminus, and an intracellular C-terminus (Figure 1.1). GPCRs are an important 
pharmacological target, with approximately one-third of small-molecule drugs approved 
by the Food and Drug Administration (FDA) targeting GPCRs.1 
 
Figure 1.1. Structure of a GPCR. When the ligand binds, the signal is transmitted 
from the outside to the inside of the cell via activation of the G-protein.  
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1.1.2 GPCR Dimers 
1.1.2.1 Discovery of GPCR Dimers 
Since the characterization of GPCRs in the 1970s-80s2,3 until the late 1990s, 
GPCRs were widely believed to exist as monomers. Due to the membrane solubilization 
technique required to isolate GPCRs from the lipid bilayer and characterize them in 
aqueous solution, GPCR dimers and oligomers were not observed, and GPCRs were 
assumed to function in a monomeric fashion. In 1998, studies4, 5 of the gamma-
aminobutyric acid (GABA) receptors GABABR1 and GABABR2 in living, recombinant 
cells revealed that when GABABR2 is not expressed, GABABR1 is not transported from 
the endoplasmic reticulum to the cell membrane; furthermore, coimmunoprecipitation 
indicated that the two receptors are colocalized on the cell membrane. The discovery that 
these two GABA receptors functioned as a heterodimer (that is, two different GPCRs 
forming one functional unit) marked a paradigm shift in the understanding of GPCRs. 
In subsequent years, recombinant cell lines were used to show the existence of 
many more GPCR heterodimers as well as homodimers (that is, two of the same GPCRs 
forming one functional unit). However, in recombinant cell lines, receptors are often 
expressed at levels much higher than they would be in vivo, and some of the early data 
has been called into question.6 Controversy persists as to whether GPCRs form higher-
order oligomers, whether GPCR dimers exist in equilibrium with monomers, and whether 
some reported GPCR dimers are functionally relevant.   
1.1.2.2 GPCR Heterodimers as Therapeutic Targets 
A major motivation in studying GPCR heterodimers is that they may prove to be 
valuable targets for novel therapeutics. GPCR heterodimers can exhibit different 
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properties than monomers or homodimers, and so modulating the activity of heterodimers 
potentially offers a new strategy in drug design. Additionally, a drug designed to target a 
heterodimer may lead to greater potency, better specificity, and fewer off-target effects.  
In some cases, one protomer of a heterodimer can allosterically modulate the 
affinity of the other protomer for a ligand. In the A2A adrenergic receptor- D2 
dopaminergic receptor heterodimer,7 for example, antagonism of A2AR increases the 
affinity of D2R for dopamine.8 Primate trials have shown that administration of an A2A 
antagonist can be used to increase affinity for constitutive dopamine, and co-
administration of an A2A antagonist with L-dopa (a precursor to dopamine) can be used to 
decrease the extent of dyskinesia that is often a side effect of L-dopa.9 
Another approach to novel therapeutics is by either inducing or interrupting the 
formation of GPCR heterodimers. For example, the µ-opioid receptor (MOR) and type 2 
cholecystokinin receptor (CCK2R) do not form constitutive heterodimers, but when 
treated with a compound bearing pharmacophores for both receptors, heterodimer 
formation is induced.10 CCK2R modulates opioid tolerance, and in proof-of-principle in 
vivo studies, this strategy was shown to reduce morphine tolerance in mice. On the other 
hand, blocking the formation of constitutive dimers can also yield a therapeutic 
advantage, though this approach has been more frequently tested in homodimers rather 
than heterodimers. In a 2005 study,11 the disruption of the formyl peptide receptor (FPR) 
of neutrophils with a peptide that inhibits the association of the transmembrane domains 
of the protomers resulted in increased superoxide production.  
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1.1.2.3 Bivalent Ligands 
A major contribution to the study of GPCR dimers from the field of chemistry has 
been the development of bivalent ligands. In these compounds, two ligands are joined 
together by a tether, also known as a linker (Figure 1.2). Bivalent ligands may either be 
homobivalent, in which both pharmacophores are the same, or heterobivalent, in which 
each pharmacophore is selective for a different receptor.  
 
Figure 1.2. Heterobivalent ligand. Two ligands, each selective for a one of the 
receptors of the dimer, are joined by a linker. 
 
Such compounds were first developed by Portoghese12 in 1982 to estimate the distance 
between opioid receptor subtypes by testing different linker lengths. The increased 
potency of the bivalent ligands in this study was attributed to the entropic advantage of 
binding the second pharamacophore of the singly-bound bivalent ligand when compared 
the entropy cost of binding a free bivalent ligand (Figure 1.3).13 The applicability to the 
study of GPCR dimers was only recognized later. 
The design of a bivalent ligand depends first upon the availability of ligands that 
are selective for each of the receptors in question. Each ligand must have a location to 
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which the tether may be attached without adversely affecting the binding and efficacy of 
the compound. To test this requirement, the ligand can be synthesized with the linker or a 
proxy for the linker in place, but without the second pharmacophore. Another important 
consideration in the design of the bivalent ligand is the type of linker.  Though this can be 
a simple hydrocarbon chain, more commonly polyethylene glycol or polyamide chains 
are used so that the molecule does not become too hydrophobic, which would pose a risk 
of entrapment in the lipophilic interior of the cell membrane. 
 
Figure 1.3. The entropic advantage of bivalent ligands. In pathway (A), a second 
heterobivalent ligand binds to the second receptor. In pathway (B), the second 
pharmacophore of the first heterobivalent ligand binds to the second receptor. Pathway 
(B) represents a lower entropic cost.  
 
1.2 Serotonin 2A and 2C Receptors 
1.2.1 Relationship to Drug Relapse 
A putative GPCR heterodimer that is of interest to our group is that of the 
serotonin (5-HT) 2A receptor (5-HT2AR) and serotonin 2C receptor (5-HT2CR) due to the 
relationship between these receptors and drug abuse relapse. The return to taking drugs 
after an extended period of abstinence is a major problem in addiction treatment, with 40-
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60% of recovering addicts experiencing at least one relapse during their recovery.14 
Relapse has been linked to impulsivity, defined as the tendency to act without 
considering negative consequences,15 and cue reactivity, defined as the tendency to 
respond to cues associated with drug-taking.16 These two factors are reduced by 
antagonism of the 5-HT2AR.17,18 The 5-HT2CR works in opposition19 to the 5-HT2AR; 
that is, agonism of the 5-HT2CR reduces impulsivity20 and cue-reactivity.21  
1.2.2 Synergism Between 5-HT2AR and 5-HT2CR 
An early indication that the 5-HT2AR and 5-HT2CR may form heterodimers was 
reported by our collaborators in a rat behavioral study.22 By co-administering a 
subthreshold dose of a 5-HT2AR antagonist (M100907) with a subthreshold dose of a 5-
HT2CR agonist (WAY163909), either of which would be ineffective on its own, 
significant changes to the rats’ behavior were observed. Specifically, rats who were 
treated with the two compounds together showed a decrease in cocaine-induced motor 
activity (though not spontaneous motor activity), a decrease in both inherent and cocaine-
induced impulsive action, and a decrease in both cue-induced and cocaine-primed 
reinstatement of cocaine self-administration (relapse). The ability of subthreshold doses 
of the two compounds to elicit a response suggests that the 5-HT2AR and 5-HT2CR act 
synergistically rather than independently of one another, and although no mechanism of 
this synergism was observable in these animal studies, a plausible explanation would be 
that the 5-HT2AR and 5-HT2CR form a heterodimer.  
1.2.3 Biological Evidence for 5-HT2AR and 5-HT2CR Dimerization 
Recent biological data provide strong evidence for the existence of 5-HT2AR and 5-
HT2CR homodimers and heterodimers.23 In cells transfected with 5-HT2AR that had been 
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linked to fluorescent proteins, bioluminescence resonance energy transfer (BRET, 
discussed below) was used to show that these receptors are in close proximity to one 
another, most likely indicating homodimerization. The same result was observed for cells 
expressing fluorescent 5-HT2CR. In cells expressing both 5-HT2AR and 5-HT2CR, not 
only was the BRET response indicative of heterodimer formation but also that 
heterodimerization is preferred over homodimerization. Co-immunoprecipitation was 
used to confirm the physical interaction of 5-HT2AR and 5-HT2CR. 
In signaling studies of the 5-HT2AR/5-HT2CR dimer, the 5-HT2CR was found to be 
dominant over the 5-HT2AR. When cells were first treated with a 5-HT2AR antagonist 
and then with 5-HT, no significant difference in signaling was detected as measured by 
the amount of downstream inositol phosphate produced; thus, deactivation of the 5-
HT2AR had no effect on signaling. However, when the cells were treated with a 5-HT2CR 
antagonist and then with 5-HT, signaling was significantly decreased; thus, 5-HT2CR is 
the main contributor to signaling. Similar results were observed in mouse neurons and in 
live mice.  
The recent finding that the 5-HT2CR is dominant over the 5-HT2AR is consistent with 
the previous observation that subthreshold doses of a 5-HT2CR agonist and 5-HT2AR 
antagonist significantly affect the impulsivity and cue reactivity of rats. Though much 
further study is needed, one possible explanation is that some monomeric or 
homodimeric 5-HT2ARs are blocked by the antagonist while others are blocked by 
heterodimerization with 5-HT2CR, leading to more deactivation of the 5-HT2AR than 
would be expected from a monomeric model of these GPCRs. 
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1.2.4 Bivalent Ligands for 5-HT2AR and 5-HT2CR 
To study the properties of 5-HT2AR and 5-HT2CR homodimers and probe the 
existence of heterodimers, bivalent ligands have been synthesized by our group (Figure 
1.4). A homobivalent ligand of the 5-HT2AR antagonist M100907 was synthesized with a 
polyethylene glycol (PEG) linker of varying lengths.24 When tested in cells expressing 
the 5-HT2AR, the bivalent ligands with linkers ranging from 12 to 18 atoms were found 
to be the most potent; this specificity of length is strong evidence for homodimerization 
because it indicates that the bivalent linker is the appropriate length to span the distance 
between the two receptors. The 5-HT2AR was later shown to form homodimers via 
biological methods.25, 26  
A heterobivalent ligand was synthesized from M100907 and WAY163909, a 5-
HT2CR agonist, to target the presumed 5-HT2AR and 5-HT2CR heterodimer.27,28 To 
accomplish this, a PEG linker bearing an azide group was attached to M100907, and a 
PEG linker bearing an alkyne group was attached to WAY163909. The two 
pharmacophores were linked via the copper-catalyzed azide-alkyne cycloaddition 
(CuACC). Ligands with various tether lengths were synthesized, and the one with the 17-
atom linker had the most promising biological activity in cells expressing both 5-HT2AR 
and 5-HT2CR, though further testing is needed to confirm this result.  
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Figure 1.4. 5-HT2AR antagonist, 5-HT2CR agonist, and bivalent ligands. (A) 
M100907, a 5-HT2AR antagonist. (B) WAY163909, a 5-HT2CR agonist. (C) 
Homobivalent M100907. The stereogenic hydroxyl group was replaced with a ketone as 
a synthetic simplification. (D) Heterobivalent M100907-WAY163909. 
 
1.3 The Use of Fluorophores in Studying GPCR Dimers 
1.3.1 Fluorescent Labelling of Monovalent Ligands and Receptors 
The use of fluorescence imaging, both with small-molecule organic fluorophores 
as well as with fluorescent proteins, has been crucial in developing an understanding of 
the existence of GPCR dimers and oligomers, their lifetime, and their size. Resonance 
energy transfer techniques (BRET and fluorescence resonance energy transfer, FRET) 
have been invaluable in the study of GPCR dimers. BRET and FRET occur via the 
transfer of energy from a donor fluorophore to an acceptor fluorophore which can only 
occur at distances of approximately 1-10 nanometers29 and decreases sharply at greater 
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distances. Thus, if the acceptor fluorophore exhibits fluorescence, then the donor and 
acceptor are close to one another.  This technique has been used to support the existence 
of many GPCR dimers, both by fluorescently labeling ligands and by fluorescently 
labeling the receptors themselves as with the 5-HT2AR/5-HT2CR heterodimer discussed 
above.23  A limitation of BRET and FRET is that it is possible for a donor and acceptor to 
be close enough to give a fluorescent signal without the two receptors being in physical 
contact; these methods can give strong support for the existence of a dimer or oligomer, 
but they are not conclusive.30  
Another technique used is fluorescence correlation spectroscopy (FCS), in which 
either fluorescence-tagged receptors or receptors bound to fluorescence-tagged ligands 
move in and out of an observation area, and the changes in fluorescence are detected over 
time.  Based on the premise that GPCR dimers move through the cell membrane more 
slowly than monomers, FCS was used to show that the 5-HT2CR forms homodimers and 
not monomers when singly expressed.31 
The introduction of super-resolution nanoscopy has opened the door to single-
molecule tracking using fluorophores. In a landmark study32 in 2010, Hern et al. 
administered a monovalent fluorescent ligand to live cells expressing the M1 muscarinic 
acetylcholine receptor and followed the movement of the receptors via video. By 
analyzing the intensity of fluorescence, both the formation and dissociation of 
homodimers was observed. This finding introduced the idea that GPCR monomers and 
dimers exist in a dynamic equilibrium. For the M1 receptor, approximately 30% of 
receptors existed as dimers at a given time, and the lifetime was about 0.5 seconds. The 
Kasai group reported similar findings for the N-formyl peptide receptor, in that the 
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lifetime was about 150 milliseconds.33 In these studies and others, fluorescence-labeled 
ligands have been valuable tools to further understand the nature of GPCR dimers.  
1.3.2 Fluorophore-tagged Bivalent Ligands 
While bivalent ligands have been a valuable tool for selectively targeting GPCR 
dimers, and fluorescence-labelled monovalent ligands have been key in imaging GPCR 
dimers via the techniques recounted above, relatively few bivalent ligands have 
incorporated a fluorophore to allow for visualization of the dimeric receptor.  In a 2010 
study, a homobivalent ligand for the chemokine receptor CXCR4 was tagged with the 
fluorophore tetramethylrhodamine.34 The linker was composed of a rigid poly-L-proline 
segment as a means of estimating the distance between the two receptors.  A lysine 
residue was incorporated into the linker so that the amine side-chain could be used as a 
handle for the second pharmacophore. The fluorophore was attached to the amino acid 
chain by means of an amide bond. A similar approach was used in the development of a 
heterobivalent ligand for the melanocortin and cholecystokinin receptors.35 The linker 
composed of flexible PEG segments and a semiflexible alternating proline-glycine 
segment, and incorporation of a lysine residue at the junction of these two segments 
provided a handle on which to attach a fluorophore (Figure 1.5 A). Cyanine (Cy5) or 
europium (Eu-DTPA) was incorporated into the linker in this way. This strategy was 
repeated by the same group in the development of a heterobivalent ligand for the 
sulfonylurea-1 receptor (SUR1) and glucagon-like peptide-1 receptor (GLP-1R), except 
rather than using a lysine side-chain as a fluorophore handle, a cysteine residue was 
used.36 The Cy5 was modified to contain a maleimide to form a bond to the sulfur atom 
of the cysteine (Figure 1.5 B). Another method of incorporating a fluorophore into a  
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Figure 1.5. Different methods of incorporating a fluorophore into a bivalent 
ligand. (A) The fluorophore is attached via the side chain of a lysine residue. (B) The 
fluorophore is attached via the side chain of a cysteine residue. (C) The fluorophore is 
attached via a modified proline residue and the copper-catalyzed azide-alkyne 
cycloaddition.  
 
poly-L-proline linker was developed by modifying one of the proline residues before 
adding it to the linker so that it contained an azide, and the fluorophore was then added 
through the copper-catalyzed azide-alkyne cycloaddition (Figure 1.5 C).37 The use of an 
amino acid as a means of incorporating a fluorophore is convenient when the linker is 
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itself composed of amino acids, especially as this strategy is compatible with solid-phase 
synthesis techniques. However, no examples exist of a fluorophore incorporated into a 
PEG-only linker. 
The incorporation of fluorophores into the bivalent ligands described above 
allowed for valuable biological information to be acquired. Cells with high expression of 
CXCR4 were distinguished from cells with medium and low expression of this receptor 
by use of the fluorescent homobivalent ligand; the monovalent ligand did not show a 
large enough difference in binding affinity to effectively distinguish among these cell 
types. As overexpression of CXCR4 has been implicated in cancer metathesis, the 
homobivalent ligand has been proposed as a cancer diagnostic. The fluorescent 
heterobivalent ligand for MC1R-CCK2R was tested in vivo in tumors grafted into the 
flanks of mice. The bivalent ligand selectively targeted the tumors expressing both 
receptors over tumors expressing only one receptor (as detected by fluorescence 
measurements), demonstrating a proof-of-principle that bivalent ligands can be used to 
enhance specificity of binding to particular cells or tissues. The fluorescent heterobivalent 
ligand for SUR1 and GLP-1R yielded similar results in pancreatic β-cells, though the 
binding was only specific at low concentrations of ligand. Additionally, in both of these 
heterobivalent studies, the fluorophore allowed for the visualization of ligand binding and 
subsequent internalization of the receptor into the cell. 
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Chapter II: Iodoalkyne Approach 
2.1 Fluorophore-tagged Bivalent Ligand 
In order to visualize the 5-HT2AR/5-HT2CR heterodimer on living cells, the 
objective of adding a fluorophore to the bivalent M100907-WAY163909 ligand was 
determined. As in the studies mentioned above,35-37 adding a fluorophore can also allow 
for the assessment of selectivity of the heterobivalent ligand for the heterodimer and 
determination of whether the ligand is internalized after binding. One important aspect 
that was considered in the design of the fluorophore-tagged ligand was keeping the 
compound as similar as possible to previously synthesized bivalent M100907-
WAY163909 ligands to minimize variability introduced into biological testing. Another 
aspect was to provide a site for the addition of a fluorophore that would be 
complementary with the functional groups available on commercially available 
fluorophores. Additionally, the fluorophore could not be too close to either ligand so that 
it would not interfere with receptor binding. 
2.2 Iodoalkyne-azide Cycloaddition Reaction 
The first approach to add a handle for a fluorophore to the bivalent M100907- 
WAY163909 ligand that would satisfy these requirements was to functionalize the 
triazole of the linker (Figure 2.1).  This strategy employed the use of the copper-catalyzed 
cycloaddition of an azide with a 1-iodoalkyne developed by Sharpless, Fokin, and 
coworkers.38 Like the copper-catalyzed azide-alkyne cycloaddition previously used by 
members of our group to synthesize the M100907-WAY163909 bivalent ligand, the iodo-
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variation makes use of orthogonal functional groups on each side of the bivalent ligand, 
which would enable the linkage of the two ligands late in the synthesis with little or no 
interference with the functional groups present on either ligand. 
 
Figure 2.1. Addition of a fluorophore to the triazole of the linker.   
The advantage of using a 1-iodoalkyne rather than a terminal alkyne is that the 5-
iodotriazole formed in the cycloaddition can be used in cross-coupling reactions, and a 
fluorophore containing the appropriate reactive functional group could then be added at 
the 5-position of the triazole via Suzuki, Heck, or Sonogashira coupling.   
 
Scheme 2.1. Synthetic plan for adding a fluorophore to the triazole of the linker.  
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Though the cycloaddition is completely regioselective for the 5-iodotriazole over the 4-
iodotriazole, the type of ligand used can greatly affect the yield of the reaction and the 
amount of prototriazole that is also formed.  
2.3 Results and Discussion 
2.3.1 Model System 
The cycloaddition of an azide and a 1-iodoalkyne was first attempted on a model 
system consisting of the linker portion of the bivalent ligand without the ligands 
themselves. The molecules to be used in the model system are shown in Figure 2.2.  
 
Figure 2.2. Iodoalkyne and azide selected as model system for cycloaddition.   
The azide had previously been synthesized in our group, as well as the alkyne that did not 
contain iodine (Scheme 2.2). The use of the tosyl group greatly increased the ultraviolet 
absorption of the compounds, making the reactions easier to follow by thin-layer 
chromatography, and when needed this group could be used as a leaving group.   
 The azide (2.2) was synthesized in two steps from starting material 2-(2-
chloroethoxy)ethanol. First, the chloride was displaced by the azide via substitution, and 
then the hydroxyl group was tosylated. The terminal alkyne (2.4) was synthesized in 
similar fashion from diethylene glycol. First, the propargyl group was added, and then the 
hydroxyl group was tosylated.  
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Scheme 2.2. Synthesis of azide and terminal alkyne.  
2.3.2 Alkyne Iodination 
The terminal alkyne 2.4 was iodinated using N-iodomorpholine hydriodide 
(Scheme 2.3) according to the method reported by Sharpless, Fokin, and coworkers.38  
 
Scheme 2.3. Iodination of terminal alkyne.  
In the reported procedure for other iodoalkynes synthesis by this method, the compounds 
were filtered through activated, neutral alumina and used in the cycloaddition reaction 
without further purification. Isolation of compound 2.5 was attempted using silica gel 
chromatography; however, the nearly identical retention factors of the product and 
starting material prevented a clean separation.  
 Though the product was not cleanly isolated, the crude 1H NMR spectrum shows 
the disappearance of the proton of the terminal alkyne. The methylene group adjacent to 
the alkyne shifts downfield and is no longer coupled to the acetylene proton. Also, low-
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resolution liquid chromatography- mass spectrometry (LC-MS) shows the expected mass 
to charge ratio of 425 for the iodoalkyne, as well as the mass to charge ratio of 299 for 
the protoalkyne. These data indicate that the iodination reaction was indeed successful.  
2.3.3 Cycloaddition 
Though the iodoalkyne could not be cleanly isolated, the cycloaddition reaction 
with the azide was attempted with the crude product of the iodination reaction following 
the one-pot, two-step protocol reported by Sharpless, Fokin, and coworkers (Scheme 
2.4).38 The crude alkyne product was filtered through celite into a pre-mixed solution of 
copper iodide and triethylamine in tetrahydrofuran. The result, as determined by LC-MS, 
was a complex mixture of the azide starting material, both the proto- and iodo- alkynes, 
and both the proto- and iodo- triazole. The desired product could not be separated from 
this complex mixture.  
 
Scheme 2.4. Cycloaddition of crude alkyne mixture with azide 2.2.  
It has been reported that the type and amount of amine ligand can determine the 
ratio of prototriazole to iodotriazole; however, since the alkyne mixture could not be 
separated, it could not be determined the extent to which iodine was lost during the 
reaction. The cycloaddition was thus attempted with commercially available 1-
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iodohexyne to ensure the purity of the iodoalkyne (purity was verified by 1H NMR before 
use). Only the iodotriazole was formed, indicating that for this model system, iodine was 
not lost during the cycloaddition.  
 
Scheme 2.5. Cycloaddition with commercially available 1-iodoalkyne.  
2.4 Conclusion 
 Given the challenges in purification and yield that were encountered in the model 
system, it was determined that the azide-iodoalkyne cycloaddition reaction would not be 
a suitable method to functionalize the linker of the bivalent M100907-WAY163909 
ligand. Because the iodinated linker could not be purified, addition of the linker to either 
M100907 or WAY163909 would result in some of the protoalkyne linker being added, 
lowering yield of the desired product late in the synthesis. Though functionalizing the 
triazole of the linker would lead to a bivalent ligand most similar to those previously 
synthesized by our group and tested on cells, the mixed results of the iodination reaction 
compromised the practicality of this approach.  
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Chapter III: Tertiary Amine Approach 
3.1 Overview of synthetic plan 
 As an alternative to the iodoalkyne-azide cycloaddition reaction, a strategy was 
developed using a tertiary amine to incorporate a handle for a fluorophore. In this 
approach, one of the oxygen atoms of the PEG linker is replaced with a nitrogen (Figure 
3.1). This nitrogen atom enables tertiary substitution without the addition of a 
stereocenter, as would be the case with a tertiary carbon. Additionally, the change from 
oxygen to nitrogen does not significantly change the polar surface area of the compound, 
which is necessary to consider as these compounds will be used for biological testing. 
 A methyl ester was chosen as the fluorophore handle to install on the linker. 
Many commercially available fluorophores contain an amine functional group, so the 
fluorophore could then be attached to the linker by an amide coupling. In fact, 
fluorophores containing an amine are more common commercially than fluorophores 
containing a boronic acid needed for Suzuki coupling, making this approach more 
versatile than the iodoalkyne approach described in Chapter 2.  
 
Figure 3.1. Tertiary amine strategy. (A) An oxygen atom in the PEG linker is substituted 
for a nitrogen to allow tertiary substitution. (B) A methyl ester is used as a handle for 
attachment of a fluorophore via amide coupling.  
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3.2 Results and Discussion 
3.2.1 Synthesis of Tertiary Amine 
 The linker with the tertiary amine was synthesized from diethylene glycol 
according to Scheme 3.1. One hydroxyl group of diethylene glycol was protected as a 
silyl ether (3.1). The other hydroxyl group was then oxidized to the aldehyde (3.2). 
Several oxidation methods were tested, including the use of 2-iodoxybenzoic acid (IBX) 
and the Swern oxidation. All methods gave comparable yields, and the use of bleach and 
(2, 2, 6, 6-tetramethylpiperidin-1-yl)oxy (TEMPO) was favored due to the short reaction 
time of two hours. 
 
Scheme 3.1. Synthesis of tertiary amine linker.  
 
 The amine group, as well as the ester for later amide coupling, were added via 
reductive amination with glycine methyl ester hydrochloride. The amination was first 
attempted under acidic conditions because such conditions have been reported to increase 
22 
 
the rate of reaction by protonating the aldehyde, which accelerates the formation of the 
imine.39 However, under acidic conditions, only a trace amount of the dialkylated amine 
was isolated (Scheme 3.2) and the desired monoalkylated amine was not formed. The 
conditions were then altered so that the glycine methyl ester hydrochloride salt was first 
mixed with one equivalent of triethylamine. The neutralized amine was then added to 
aldehyde 3.2 along with sodium triacetoxyborohydride (STAB), which gave the desired 
secondary amine (3.3) in good yield.  
 
Scheme 3.2. Reductive amination under acidic conditions yielded a dialkylated amine.  
The alkyne needed for the joining of the two ligands via the CuAAC was then added 
using propargyl bromide, forming tertiary amine 3.4. Deprotection of the hydroxyl group 
was then accomplished using tetrabutylammonium fluoride to give compound 3.5. 
3.2.2 Synthesis of M100907 Derivative 
 The 5-HT2AR antagonist M100907 was selected over the 5-HT2CR agonist 
WAY163909 as the pharmacophore of the bivalent ligand to which to add the 
functionalized linker. WAY163909 contains a secondary amine, which would need to be 
differentially protected before the amide coupling of the fluorophore to the linker.  
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M100907 could be synthesized according to the method reported by Rice40 without the 
need for additional protection.  
 To synthesize the M100907 derivative, guaiacol was first protected as a silyl ether 
(3.6) and then coupled to Weinreb amide 3.7 to install the piperidine moiety (Scheme 3.3, 
3.4). Deprotection of the amine and reduction of the ketone yielded racemic alcohol 3.10. 
Chiral resolution was accomplished with (R)-mandelic acid according to the method 
reported by our group to give 3.11 as a single enantionmer.28  The fluorine-substituted 
phenyl ring was added to yield 3.13, which when deprotected gave 3.14, a derivative of 
M100907. 
 
Scheme 3.3. Synthesis of a derivative of 5-HT2AR antagonist M100907.  
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Scheme 3.4. Synthesis of compounds 3.7 and 3.12.  
3.2.3 Attachment of Functionalized Linker to M100907 Derivative 
To attach the linker to M100907, the hydroxyl group was tosylated to form a 
leaving group (Scheme 3.5). The tosylation reaction proceeded in moderate yield, and 
unreacted starting material was recovered.  
 
Scheme 3.5. Tosylation of tertiary amine.  
Attempts to add the tosylated linker to M100907 were unsuccessful (Scheme 3.6). The 
first trial used sodium hydride as the base in dimethyl formamide, as these were the 
conditions used to add the non-functionalized PEG linker to M100907.28 The procedure 
was repeated with potassium hexamethyldisilane (KHMDS). This base was chosen 
because of its different counterion and comparative ease of handling. The second attempt 
was also unsuccessful, indicating that a different leaving group may be necessary. 
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Leaving groups such as bromide, mesylate, or triflate could be added in one step from 
compound 3.5.  
 
Scheme 3.6. Attachment of tosylated linker to 3.14 was attempted with NaH and 
KHMDS as the base.  
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Chapter IV: Conclusion and Future Work 
 To functionalize the PEG linker of the bivalent ligand of M100907 and 
WAY163909, a linker (3.5) was synthesized containing a tertiary amine, which allowed 
for the inclusion of an ester side-chain.  This ester is intended to be a handle for 
incorporation of a fluorophore via amide coupling, which will open the door to cellular 
imaging with this bivalent ligand and a greater understanding of the putative 5-HT2AR/5-
HT2CR GPCR heterodimer. The use of a tertiary amine was shown to be more promising 
than the attempt to functionalize the linker at the triazole.  
 With the functionalized linker in hand, the next step is to add the functionalized 
linker to M100907. Use of the tosylate as the leaving group was shown to be ineffective, 
so other leaving groups should be tested, such as bromide and triflate. Once the linker is 
attached to M100907, the fluorophore can be added to the linker, and then the CuAAC 
can be used to join the compound with WAY163909. Biological imaging of the 
fluorophore-tagged bivalent ligand can be used to assess the selectivity for the 5-HT2AR - 
5-HT2CR GPCR heterodimer over 5-HT2AR and 5-HT2CR monomers or homodimers, or 
to see if the ligand-receptor complex is internalized. 
 This functionalized linker, though developed for study of the 5-HT2AR/5-HT2CR 
heterodimer, would be compatible with any bivalent ligand that uses PEG as a tether in 
conjunction with the CuAAC.  (In cases where the ligand has a free amine, such as the 
case of WAY163909, this may require additional protecting groups.) PEG is a commonly 
used tether due to its availability, flexibility, and hydrophilicity in comparison to a 
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hydrocarbon chain. Thus, the fluorophore-tagged tertiary amine linker is a general tool 
that can be used in the study of many different GPCR dimers.  
 Though the original intent of the functionalized linker was for the addition of a 
fluorophore, many other moieties can be added through the formation of an amide bond. 
In this sense, the linker can be used to make trivalent ligands. One possibility would be to 
add biotin to the bivalent ligand, which could be used with streptavidin to isolate the 
heterodimer. The azide, the alkyne, and the amide components of the trivalent ligand are 
all interchangeable, making this tertiary amine linker a truly versatile tool.  
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Chapter V: Experimental Section 
5.1 General Methods 
All starting materials and reagents were purchased from Sigma-Aldrich, Acros, 
AstaTech, and Aapptec and unless noted were used without further purification. Thin-
layer chromatography (TLC) was performed on Silicycle glass backed plates (extra hard 
layer, 250 mm thick, 60 Å, with F-254 indicator) and components were visualized by UV 
light (254 nm) and/or p-anisaldehyde, basic permanganate (KMnO4) solution or 
ninhydrin solution. Flash column chromatography was performed using Silicycle silica 
gel (particle size 40-63 mm, 230-400 mesh). NMR spectra were obtained using JEOL 
ECX-400 spectrometer (400 MHz for 1H NMR and 101 MHz for 13C NMR), JEOL 
ECA-500 spectrometer (500 MHz for 1H NMR and 126 MHz for 13C NMR), or JEOL 
ECA-600 spectrometer (600 MHz for 1H NMR and 151 MHz for 13C NMR). Chemical 
shifts were referenced to the residual chloroform-H peak at 7.26 ppm (1H) and 77 ppm 
(13C) in CDCl3. Chemical shifts were reported in parts per million (ppm, δ). Multiplicity 
were indicated as s for singlet, d for doublet, t for triplet, q for quartet, m for multiplet, br 
for broad resonance and the coupling constants (J) were reported in Hz.  
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5.2 Experimental Procedures 
 
 
2-(2-(3-iodoprop-2-ynyloxy)ethoxy)ethyl 4-methylbenzenesulfonate (2.5): 2-(2-(prop-
2-ynyloxy)ethoxy)ethyl 4-methylbenzenesulfonate (959 mg, 3.2 mmol) was dissolved in 
anhydrous THF (8 mL). Copper iodide (30 mg, 0.16 mmol) and N-iodomorpholine 
hydriodide (1.193 g, 3.5 mmol) were added. The reaction was stirred at room temperature 
under a nitrogen atmosphere for two hours, forming a white precipitate. The reaction 
mixture was filtered through celite and rinsed with DCM.  Concentration under reduced 
pressure yielded the crude product as a brown oil. Purification attempts were 
unsuccessful. 
 
 
2-(2-((5-iodo-1-(2-(2-(tosyloxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-
yl)methoxy)ethoxy)ethyl 4-methylbenzenesulfonate (2.6): Copper iodide (6 mg, 0.03 
mmol) and triethylamine (61 mg, 0.6 mmol) were stirred together in THF (2 mL), 
forming a blue-green solution. Crude 2-(2-(3-iodoprop-2-ynyloxy)ethoxy)ethyl 4-
methylbenzenesulfonate (approximately 127 mg, 0.3 mmol) was dissolved in THF (1.5 
mL) and added to the reaction mixture. 2-(2-azidoethoxy)ethyl 4-methylbenzenesulfonate 
(86 mg, 0.4 mmol) was dissolved in THF (1.5 mL) and added to the reaction mixture. 
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The reaction was stirred at room temperature under a nitrogen atmosphere for two hours. 
The reaction was quenched with 0.5 mL of saturated ammonium hydroxide. The volatile 
components were removed under reduced pressure. The reaction mixture was suspended 
in water and diethyl ether and stirred for 20 minutes. The reaction mixture was extracted 
three times with diethyl ether.  The organic layers were combined and dried with sodium 
sulfate. Filtration and concentration under reduced pressure yielded the crude product. 
Purification attempts were unsuccessful. 
 
2-(2-(tert-butyldiphenylsilyloxy)ethoxy)ethanol (3.1): Diethylene glycol (6.00 g, 56.6 
mmol) was added to a flame-dried round-bottom flask. Anhydrous DCM (38 mL) was 
added, then tert-butyldiphenylsilyl chloride (2.198 g, 8.0 mmol), imidazole (1.362 g, 20 
mmol), and DMAP (20 mg, 0.16 mmol). The reaction was stirred at room temperature 
under an atmosphere of nitrogen for 22 hours. The reaction mixture was quenched with 
water and extracted with DCM. The organic layers were combined and dried with sodium 
sulfate. Filtration and concentration under reduced pressure yielded the crude product, 
which was purified by column chromatography (30% ethyl acetate in hexanes) to afford 
the product as a colorless oil (2.180 g, 79% yield). 1H NMR (500 MHz, CDCl3) δ 7.69 
(dd, J = 7.8, 1.5 Hz, 4H), 7.46 – 7.36 (m, 6H), 3.83 – 3.79 (m, 2H), 3.71 (dd, J = 9.4, 5.6 
Hz, 2H), 3.64 – 3.57 (m, 4H), 2.20 (t, J = 6.2 Hz, 1H), 1.05 (s, 9H).13C NMR (126 MHz, 
CDCl3) δ 135.70, 133.60, 129.80, 127.78, 72.47, 72.29, 63.61, 62.02, 26.89, 19.28.  
 
 35   
 
 
2-(2-(tert-butyldiphenylsilyloxy)ethoxy)acetaldehyde (3.2): 2-(2-(tert-
butyldiphenylsilyloxy)ethoxy)ethanol (1.912 g, 5.6 mmol) was dissolved in DCM and 
placed in an ice bath for fifteen minutes. TEMPO (9.4 mg, 0.06 mmol) was added. 
Sodium bromide (628 mg, 6.1 mmol) was dissolved in saturated, aqueous sodium 
bicarbonate (28 mL), and the solution was added to the reaction mixture. Sodium 
hypochlorite (10-15% aqueous solution, 3.3 mL) was added dropwise, and the reaction 
mixture turned a light brown color. The ice bath was removed, and the reaction was 
stirred at room temperature for three hours, at which point the reaction mixture had 
turned white.  The reaction mixture was extracted with DCM. The organic layers were 
combined and dried with sodium sulfate. Filtration and concentration under reduced 
pressure yielded the crude product, which was purified by column chromatography (20% 
ethyl acetate in hexanes) to afford the product as a colorless oil (1.578 g, 83% yield). 1H 
NMR (400 MHz, CDCl3) δ 9.71 (t, 1H), 7.76 – 7.60 (m, 4H), 7.49 – 7.32 (m, 6H), 4.15 
(d, J = 0.7 Hz, 2H), 3.85 (dd, J = 5.4, 4.4 Hz, 2H), 3.68 (dd, J = 5.5, 4.3 Hz, 2H), 1.05 (s, 
9H). 13C NMR (151 MHz, CDCl3) δ 201.26, 135.68, 133.47, 129.83, 127.80, 76.95, 
73.22, 63.62, 26.89, 19.26. LC-MS Calculated for C20H26O3Si [M+H]+ 343; found: 343. 
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Methyl 2,2-dimethyl-3,3-diphenyl-4,7-dioxa-10-aza-3-siladodecan-12-oate (3.3): 
Glycine methyl ester hydrochloride (904 mg, 7.2 mmol), triethylamine (729 mg, 7.2 
mmol), and anhydrous dichloromethane (55 mL) were added to an evaporation flask and 
mixed using a syringe. The mixture was added to 2-(2-(tert-
butyldiphenylsilyloxy)ethoxy)acetaldehyde (1.875 g, 5.5 mmol). Sodium 
triacetoxyborohydride (3497 mg, 16.5 mmol) was added in four portions over one hour. 
The reaction was stirred at room temperature under nitrogen for 18 hours. The reaction 
was quenched with water and extracted with dichloromethane. The organic layers were 
combined and dried with sodium sulfate. Filtration and concentration under reduced 
pressure yielded the crude product, which was purified by column chromatography 
(100% ethyl acetate) to afford the product as a colorless oil (1.501 g, 66% yield). 1H 
NMR (500 MHz, CDCl3) δ 7.72 – 7.65 (m, 4H), 7.45 – 7.35 (m, 6H), 3.81 (t, 2H), 3.71 
(s, 3H), 3.61 – 3.55 (m, 4H), 3.45 (s, 2H), 2.78 (t, 2H), 1.05 (s, 9H). 13C NMR (126 
MHz, CDCl3) δ 172.79, 135.70, 133.77, 129.70, 127.73, 72.33, 70.77, 63.48, 51.86, 
50.96, 49.05, 26.89, 19.29. LC-MS Calculated for C23H33NO4Si [M+H]+: 416; found: 
416. 
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Methyl 2,2-dimethyl-3,3-diphenyl-10-(prop-2-ynyl)-4,7-dioxa-10-aza-3-siladodecan-
12-oate (3.4): Methyl 2,2-dimethyl-3,3-diphenyl-4,7-dioxa-10-aza-3-siladodecan-12-oate 
(703 mg, 1.7 mmol) was dissolved in acetone (17 mL). Potassium carbonate (235 mg, 1.7 
mmol) and propargyl bromide solution (80 weight percent in toluene, 0.21 mL, 1.9 
mmol) were added to the reaction mixture. The reaction was stirred under nitrogen at 
room temperature for 18 hours. The reaction was quenched with water and extracted with 
dichloromethane. The organic layers were combined and dried with sodium sulfate. 
Filtration and concentration under reduced pressure yielded the crude product, which was 
purified by column chromatography (20% ethyl acetate in hexanes) to afford the product 
as a slightly yellow-tinted oil (590 mg, 77% yield). 1H NMR (500 MHz, CDCl3) δ 7.81 – 
7.56 (m, 4H), 7.45 – 7.35 (m, 6H), 3.78 (t, J = 5.2 Hz, 2H), 3.68 (s, 3H), 3.64 (t, J = 5.6 
Hz, 2H), 3.60 (d, J = 2.3 Hz, 2H), 3.55 (dd, J = 9.6, 4.5 Hz, 2H), 3.50 (s, 2H), 2.83 (t, J = 
5.5 Hz, 2H), 2.22 (t, J = 2.3 Hz, 1H), 1.04 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 
171.53, 135.70, 133.74, 129.70, 127.74, 78.76, 73.45, 72.37, 70.26, 63.44, 55.02, 53.30, 
51.73, 43.85, 26.89, 19.27. LC-MS Calculated for C26H35NO4Si [M+H]+: 454; found: 
454. 
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Methyl 2-((2-(2-hydroxyethoxy)ethyl)(prop-2-ynyl)amino)acetate (3.5): Methyl 2,2-
dimethyl-3,3-diphenyl-10-(prop-2-ynyl)-4,7-dioxa-10-aza-3-siladodecan-12-oate (590 
mg, 1.3 mmol) was dissolved in anhydrous tetrahydrofuran (13 mL). The reaction 
mixture was cooled in an ice bath for 20 minutes. Tetrabutylammonium fluoride (1.0 M 
in tetrahydrofuran, 2.0 mmol) was added to the reaction mixture. The reaction was 
removed from ice at stirred under nitrogen at room temperature for 24 hours. The 
reaction was quenched with water and extracted with dichloromethane. The organic 
layers were combined and dried with sodium sulfate. Filtration and concentration under 
reduced pressure yielded the crude product, which was purified by column 
chromatography (6% methanol in dichloromethane) to afford the product as a brownish 
oil (241 mg, 86% yield). 1H NMR (500 MHz, CDCl3) δ 3.75 – 3.69 (m, 5H), 3.66 (dd, J 
= 12.2, 6.9 Hz, 2H), 3.61 (d, J = 2.4 Hz, 2H), 3.57 (dd, J = 5.9, 3.1 Hz, 2H), 3.49 (s, 2H), 
2.90 – 2.83 (m, 2H), 2.25 (t, J = 2.3 Hz, 1H), 1.75 (s, 1H). 13C NMR (151 MHz, CDCl3) 
δ 171.48, 78.42, 73.69, 72.42, 69.30, 61.94, 54.95, 53.22, 51.90, 43.65. LC-MS 
Calculated for C10H17NO4 [M+H]+: 216; found: 216. 
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Methyl 2-(prop-2-ynyl(2-(2-(tosyloxy)ethoxy)ethyl)amino)acetate (3.15): Methyl 2-
((2-(2-hydroxyethoxy)ethyl)(prop-2-ynyl)amino)acetate (241 mg, 1.1 mmol) was 
dissolved in anhydrous dichloromethane (11 mL). The reaction mixture was cooled in an 
ice bath for 20 minutes. Triethylamine (172 mg, 1.7 mmol) and dimethylaminopyradine 
(6 mg, 0.05 mmol) were added to the reaction mixture. p-Toluenesulfonyl chloride (324 
mg, 1.7 mmol) was added portionwise over 15 minutes. The reaction mixture was 
removed from the ice bath and was stirred under nitrogen at room temperature for 24 
hours. The reaction was quenched with water and extracted with dichloromethane. The 
organic layers were combined and dried with sodium sulfate. Filtration and concentration 
under reduced pressure yielded the crude product, which was purified by column 
chromatography (1% methanol in dichloromethane) to afford the product as a white foam 
(198 mg, 48%). 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.1 Hz, 2H), 7.15 (d, J = 7.9 
Hz, 2H), 4.99 – 4.86 (m, 4H), 4.20 – 4.07 (m, 4H), 4.07 – 3.98 (m, 2H), 3.95 – 3.85 (m, 
2H), 3.76 (s, 3H), 2.99 (t, J = 2.4 Hz, 1H), 2.34 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 
165.02, 143.65, 139.53, 128.78, 125.85, 83.24, 70.54, 60.30, 58.31, 56.81, 53.37, 51.36, 
21.33. The signals at 60.30 and 58.31 ppm each represent two carbons, as indicated on 
the HMQC spectrum. LC-MS Calculated for C17H23NO6S [M+H]+: 370; found: 370. 
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5.3 NMR Spectra 
For the following NMR spectra, the horizontal axis represents the chemical shift in ppm, 
and the vertical axis represents signal intensity (a unitless quantity).  
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